Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 6/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18627908 | 1.00 | SYK (0.47) | SYKCDK2SMG1CDK1FLT3 | |
| SCHEMBL18627910 | 1.00 | SYK (0.47) | SYKCDK2SMG1CDK1FLT3 | |
| SCHEMBL18627918 | 0.91 | SYK (0.45) | SYKCDK2SMG1CDK1FLT3 | |
| SCHEMBL18627919 | 0.90 | SYK (0.43) | SYKCDK2SMG1CDK1FLT3 | |
| SCHEMBL18627896 | 0.90 | SYK (0.43) | SYKCDK2SMG1CDK1FLT3 | |
| SCHEMBL18627930 | 0.90 | SYK (0.43) | SYKCDK2SMG1CDK1FLT3 | |
| SCHEMBL18627901 | 0.89 | SYK (0.49) | SYKCDK2SMG1CDK1CDK9 | |
| SCHEMBL18627914 | 0.89 | SYK (0.49) | SYKCDK2SMG1CDK1CDK9 | |
| SCHEMBL18627956 | 0.89 | SYK (0.49) | SYKCDK2SMG1CDK1CDK9 | |
| SCHEMBL18627899 | 0.89 | SYK (0.46) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | claimed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | claimed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | claimed |
| EP-3350176-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2018-07-25 | — | — | EP | claimed |
| WO-2017046302-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2017-03-23 | — | — | WO | claimed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | claimed |
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | disclosed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | disclosed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | disclosed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | disclosed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | disclosed |
| EP-3350176-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046302-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2017-03-23 | — | — | WO | disclosed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | SYK, BTK, LCK | SYK 1/4885CDK2 841/4885SMG1 968/4885 |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | SYK, BTK, LCK | SYK 1/4885CDK2 821/4885SMG1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.